Companies
Companies
Lonza Acquires Genentech’s $12B Biologics Site
📢 Lonza buys Genentech's CA biologics manufacturing site for $1.2B, boosting production capabilities for next-gen therapies. 🏭
Revolutionary Oral Drug Restores Muscle Function
🔬 NDM Pharma & Aarhus University created NMD670, a drug that enhances communication between neurons and muscles in Myasthenia gravis. 🧠💪
Roche’s €90m Gene Therapy Hub Revolutionizes Research
Roche opens €90m gene therapy development centre in Germany 🏢🧬💉💊 to advance gene therapy research worldwide 🌍.
AstraZeneca Buys Fusion Therapeutics for $2 Billion Revolutionizing Cancer Treatment
🔬 AstraZeneca is acquiring Fusion Therapeutics Inc for $2 billion upfront to transform cancer treatment with targeted therapies. 💰🌟
Exeter Startup Raises £37m for Revolutionary Anti-Aging Drug
🌱 Exeter-based startup Senisca Ltd has raised £3.7m in seed funding to develop its senotherapeutic drug pipeline. 💉💰
Syngene’s India Biologics Facility Ready by Mid-Year
📢 Syngene International's new biologics manufacturing facility in India to be operational from mid-year. 💉🏭 Tripled capacity, expansion plans underway!
NanoString Acquired Slide Tags in Early Access Cellares Revolutionizes Cell Therapy Manufacturing!
👥 Authors: Alex Philippidis, Uduak Thomas, Jonathan D. Grinstein, PhD, and Corinna Singleman, PhD. 🗓️ Published on March 15, 2024. 💼 NanoString acquired, Slide Tags enter early access as Curio Trekker, and Cellares reveals cell therapy manufacturing platform.
Unlocking Biosimilars: Affordable Medicines for Global Health
💉 Affordable access to key medicines as patents expire. 👩⚕️ Regulatory hurdles and defensive tactics hinder US growth. 👨🔬 QTL technology improves consistency. 💰 Lower costs for biosimilars. 🚀 Attractive investment opportunity.
Game-Changing Cancer Immunotherapy Deal Unveiled
📰 Domain Therapeutics and Chime Biologics join forces to develop an anti-CCR8 antibody for cancer immunotherapy! 👥💉 Exciting times ahead! 🤝
AstraZeneca Acquires Amolyt Pharma for $105bn!
📢 AstraZeneca to acquire Amolyt Pharma for $1.05bn 💼💰 with $800m upfront and potential milestone payments of $250m. Amazing news for biotech in France and Europe!
